Sydney, Aug 15, 2006 AEST (ABN Newswire) - The August 2006 edition of our Health & Life Science Quarterly Blue Book profiles niche life sciences companies, with a focus on company strategies, key projects and significant milestones. Some financial data is also presented. In our feature article in this issue we look at how the nature of the shareholders on a company's register, and the way a company handles communications with its shareholders, can provide investors useful information about biotechnology stocks.

The following company profiles have been covered by the report;

Agenix Limited (ASX: AGX)
Analytica (ASX: ALT)
EQiTX (ASX: EQX)
Genetic Technologies (ASX: GTG)
Metabolic Pharmaceuticals (ASX: MBP)
Narhex Life Sciences (ASX: NLS)
Phylogica (ASX: PYC)
Psiron (ASX: PSX)
pSivida (ASX: PSD)
Rockeby biomed Limited (ASX: RBY)
Solagran (ASX: SLA)
Virax (ASX: VHL)

To download the report, please visit;
www.aer.com.au

NB: This report has been commissioned and as such Aegis has received a fee for its publication. However, under no circumstances has Aegis been influenced, either directly or indirectly, in making statements and/or recommendations contained in this report.

Contact

Peter Leodaritsis
Managing Director
Aegis Equities Research
www.aer.com.au


Related Companies

Solagran Limited       
Resapp Health Ltd
Psivida Limited   
Psiron Ltd
Prescient Therapeutics Ltd             
Phylogica Limited          
Pathway Biomed Limited
Metabolic Pharmaceuticals Limited
Genetic Technologies Limited       
Analytica Limited
Agenix Limited      
Aegis Equities Research

ABN Newswire This Page Viewed:  (Last 7 Days: 3) (Last 30 Days: 23) (Since Published: 11587) 
ANALYTICS: LOGIN HERE

NEWS: RECENT VISITS (23)